|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
A useful approach, aimed at maintaining analgesia and mitigating side effects, is represented by the use of a new class of analgesics endowed of µ-opioid (MOR) receptor agonism and noradrenaline reuptake inhibition (NRI) mechanisms.
|
30667206 |
2019 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Reduction of the opioid analgesia in diabetic neuropathic pain (DNP) results from μ-opioid receptor (MOR) reserve reduction.
|
31024314 |
2019 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tapentadol is a molecule incorporating mu opioid receptor agonism and norepinephrine reuptake inhibition to provide analgesia, with the potential for a lower incidence of gastrointestinal side effects than full mu opioid agonists.
|
31617931 |
2019 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our objective was to discover a novel enhancer of ligand-induced MOR endocytosis and determine its effects on analgesia, tolerance and dependence.
|
30787373 |
2019 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
In preclinical animal models, coadministration of traditional kappa opioid receptor (KOR)-targeting agonists with MOR-targeting analgesics can decrease reward and potentiate analgesia.
|
31492823 |
2019 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oliceridine is a novel G protein-biased μ-opioid receptor agonist designed to provide analgesia with an improved safety and tolerability profile.
|
31162798 |
2019 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this article we aimed to fully examine the association between OPRM1 A118G (rs1799971) polymorphism and opioid analgesia by analyzing published information.
|
30028366 |
2019 |
|
Agnosia for Pain
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In particular, the MOR component of tapentadol activity predominantly allows for analgesia in nociceptive pain; on the other hand, the NRI component contributes, now in a predominant manner, for analgesic efficacy in cases of neuropathic pain states.
|
31190962 |
2019 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
The G protein-coupled μ-opioid receptor (μ-OR) mediates the majority of analgesia effects for morphine and other pain relievers.
|
31141214 |
2019 |
|
Agnosia for Pain
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Most clinically used opioids are thought to induce analgesia through activation of the mu opioid receptor (MOR).
|
31170174 |
2019 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
At lower doses (0.003-0.03 mg/kg, s.c.) morphine induced mechanical hyperalgesia, while higher doses (1-10 mg/kg, s.c.) induced analgesia.Intrathecal (i.t.) oligodeoxynucleotide (ODN) antisense to mu-opioid receptor (MOR) mRNA, attenuated both hyperalgesia and analgesia.
|
30529265 |
2019 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although kratom produces analgesia through binding of mitragynine and other alkaloids at the mu-opioid receptor (MOR), the association of long-term kratom use with adverse opioid-like effects remains unknown.
|
31014959 |
2019 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
It provided analgesia at least as good as that of conventional strong opioids and appeared more favourable in terms of gastrointestinal tolerability, likely due to less potent MOR binding.
|
30471002 |
2018 |
|
Agnosia for Pain
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In brief, we put forward that the distinctions among baseline latency, opioid-induced tolerance, analgesia and physical dependence in male and female mice might correlate with sex associated differential expressions of OPRM1 gene.
|
30359988 |
2018 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
PolyMorphine was also shown to act through the mu opioid receptor due to the ability of naloxone (a mu opioid receptor antagonist) to block PolyMorphine-induced analgesia in spared nerve injury animals pretreated with PolyMorphine.
|
29108465 |
2018 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The 6 principles are (1) coactivation of neuronal and inflammatory immune receptors (Toll-like receptor 4), (2) 1 receptor activating cyclic adenosine monophosphate and β-arrestin second messenger systems, (3) convergence of opioid and adrenergic receptor types on 1 second messenger, (4) antagonist (eg, naltrexone)-induced receptor trafficking, (5) genetic μ-opioid receptor variants influencing analgesia and tolerance, and (6) cross-tolerance vs receptor antagonism as the basis of OUD pharmacotherapy with methadone or buprenorphine vs naltrexone.
|
29710079 |
2018 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Assays of plasma concentrations of morphine and metabolites (morphine 3-glucuronide and morphine 6-glucuronide) were performed and common polymorphisms in four candidate genes [OPRM1 rs1799971" genes_norm="1312;4988">A118G rs1799971; P-glycoprotein (ABCB1) T3435C (rs1045642) and G2677T/A (rs2032582); COMT rs4680;s4680" genes_norm="1312;4988">Val 158 Met (rs4680)] were analysed.Morphine was titrated by staff in the postanaesthesia care unit (PACU) and in the ward patient-controlled intravenous analgesia was used for 24 h.
|
29474345 |
2018 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peripherally acting μ-opioid receptor antagonists target the μ-opioid receptor without reversing analgesia.
|
29016552 |
2018 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this prospective study is to test the hypothesis that duration of epidural fentanyl analgesia differs in nulliparous women requesting epidural analgesia in early labor who are variant allele carriers of the OPRM1 SNVs 118A>G rs1799971, IVS2+31G>A rs9479757, and IVS2+691G>C rs2075572.
|
29756748 |
2018 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, (±)-N-(3-fluoro-1-phenethylpiperidine-4-yl)-N-phenyl propionamide (NFEPP), a newly designed μ-opioid receptor (MOR) agonist with a low pKa, has been shown to produce injury-restricted analgesia in models of inflammatory and postoperative pain, without exhibiting typical opioid side effects.
|
29994988 |
2018 |
|
Agnosia for Pain
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Opioids evoke analgesia through activation of opioid receptors (predominantly the μ opioid receptor) in the central nervous system.
|
29273520 |
2018 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
BAM22, a bivalent agonist of MrgC and opioid receptors, enhanced the interaction between MrgC11 and MOR and produced stronger analgesia than did the individual monovalent agonists.
|
29921657 |
2018 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
While mu opioid receptor (MOR) agonists are especially effective as broad-spectrum pain relievers, it has been exceptionally difficult to achieve a clear separation of analgesia from many problematic side effects.
|
30199635 |
2018 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, intrathecal application of the TM3<sub>MOR</sub>-TAT peptide alleviated CCK-8-injection-induced antagonism to morphine analgesia in rats.
|
29780163 |
2018 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mu-opioid Receptor (MOR) Biased Agonists Induce Biphasic Dose-dependent Hyperalgesia and Analgesia, and Hyperalgesic Priming in the Rat.
|
30342200 |
2018 |